593 18. Comins, C. et al. Clin. Cancer Res. 16, 5564–5572 (2010). 19. Breitbach, C.J. et al. Hum. Gene Ther. 22, A12 (2011). 20. Kaufman, H.L. & Bines, S.D. Future Oncol. 6, 941– 949 (2010). 21. Heo, J. et al. Mol. Ther. 19, 1170–1179 (2011). 22. Breitbach, C.J. et al. Nature 477, 99–102 (2011). 23. Gaspar, H.B. et al. Sci. Transl. Med. 3, 97ra79 (2011). 24. Hacein-Bey-Abina, S. et al. N. Engl. J. Med. 363, 355–364 (2010). 25. Gaspar, H.B. et al. Sci. Transl. Med. 3, 97ra80 (2011). 26. Aiuti, A. et al. N. Engl. J. Med. 360, 447–458 (2009). 27. Grez, M. et al. Mol. Ther. 19, 28–35 (2011). 28. Boztug, K. et al. N. Engl. J. Med. 363, 1918–1927 (2010). 29. Galy, A. & Thrasher, A.J. Curr. Opin. Allergy Clin. Immunol. 11, 545–550 (2011). 30. Cavazzana-Calvo, M. et al. Nature 467, 318–322 (2010). 31. Porter, D.L., Levine, B.L., Kalos, M., Bagg, A. & June, C.H. N. Engl. J. Med. 365, 725–733 (2011). 32. Kochenderfer, J.N. et al. Blood 119, 2709–2720 (2012). 33. Di Stasi, A. et al. N. Engl. J. Med. 365, 1673–1683 (2011). 34. Harrington, K.J. et al. Clin. Cancer Res. 16, 4005– 4015 (2010). 35. Senzer, N.N. et al. J. Clin. Oncol. 27, 5763–5771 (2009). 1. Abstracts Collaborative Meeting of the European Society of Gene and Cell Therapy and the British Society for Gene Therapy. Hum. Gene Ther. 22, A1– A138 (2011). 2. Bainbridge, J.W. et al. N. Engl. J. Med. 358, 2231– 2239 (2008). 3. Maguire, A.M. et al. N. Engl. J. Med. 358, 2240–2248 (2008). 4. Maguire, A.M. et al. Lancet 374, 1597–1605 (2009). 5. Nathwani, A.C. et al. N. Engl. J. Med. 365, 2357– 2365 (2011). 6. Raj, D., Davidoff, A.M. & Nathwani, A.C. Expert Rev. Hematol. 4, 539–549 (2011). 7. Booth, C., Gaspar, H.B. & Thrasher, A.J. Curr. Opin. Pediatr. 23, 659–666 (2011). 8. Cartier, N. et al. Science 326, 818–823 (2009). 9. Cirak, S. et al. Lancet 378, 595–605 (2011). 10. Aartsma-Rus, A. et al. Eur. J. Hum. Genet. 18, 889– 894 (2010). 11. Jessup, M. et al. Circulation 124, 304–313 (2011). 12. Sheehy, S.H. et al. Mol. Ther. 19, 2269–2276 (2011). 13. Schaller, T. et al. PLoS Pathog. 7, e1002439 (2011). 14. Li, H. et al. Nature 475, 217–221 (2011). 15. Perez, E.E. et al. Nat. Biotechnol. 26, 808–816 (2008). 16. Stroncek, D.F. et al. J. Transl. Med. 10, 48 (2012). 17. Gollamudi, R. et al. Invest. New Drugs 28, 641–649 (2010). be controlled by cognate promoters to allow physiological regulation of activity. Indeed, for many disorders the profile of gene expression required to achieve significant therapeutic effect is achievable with relatively simple expression systems. For example, the frequency of spontaneous hemorrhage is greatly reduced in hemophilia B with a small fraction of normal circulating levels of FIX. Similarly, a fraction of functional circulating phagocytes is sufficient to offer substantial protection against infection in some inherited immunodeficiencies. Diseases most amenable to effective treatment with current gene therapy approaches may therefore be those where the therapeutic window for functional protein expression is relatively broad, and where a large number of target cells are accessible to transduction. Previous expectations that gene therapy would produce a ‘cure-all’ solution for intractable diseases were unrealistic. The agents in question are a diverse spectrum of nucleic-acid based medicines that are formulated in very different ways, yet can be used to prevent, alleviate and provide long-lasting treatments for a wide variety of diseases both inherited and acquired. In some cases they can now realistically provide physicians and patients with new therapeutic options where more conventional approaches have failed, a testament to the huge amount of scientific research in the field over the last 10–20 years. By decreasing the requirement for frequent repeated interventions, many gene therapy approaches can lead to substantial savings in the costs of lifetime medication. However, it is also noteworthy that without clinical trials, the field would not have progressed nearly so rapidly. The fact that some gene therapy strategies are finally beginning to deliver on their potential may well herald a raft of new and imaginative interventional approaches designed to exploit recent insights into cell biology and disease processes.
[1]
Jens Boch,et al.
Regulation of selected genome loci using de novo-engineered transcription activator-like effector (TALE)-type transcription factors
,
2010,
Proceedings of the National Academy of Sciences.
[2]
Philip Bradley,et al.
The Crystal Structure of TAL Effector PthXo1 Bound to Its DNA Target
,
2012,
Science.
[3]
Nieng Yan,et al.
Structural Basis for Sequence-Specific Recognition of DNA by TAL Effectors
,
2012,
Science.
[4]
Matthew J. Moscou,et al.
A Simple Cipher Governs DNA Recognition by TAL Effectors
,
2009,
Science.
[5]
Monya Baker,et al.
Gene-editing nucleases
,
2011,
Nature Methods.
[6]
Jens Boch,et al.
Breaking the Code of DNA Binding Specificity of TAL-Type III Effectors
,
2009,
Science.
[7]
A. Bogdanove,et al.
TAL Effectors: Customizable Proteins for DNA Targeting
,
2011,
Science.
[8]
An Xiao,et al.
Heritable gene targeting in zebrafish using customized TALENs
,
2011,
Nature Biotechnology.
[9]
Elo Leung,et al.
A TALE nuclease architecture for efficient genome editing
,
2011,
Nature Biotechnology.
[10]
G. Church,et al.
Efficient construction of sequence-specific TAL effectors for modulating mammalian transcription.
,
2011,
Nature biotechnology.